Insufficiency of nigrostriatal dopaminergic system as a disregulation mechanism of dopamine-dependent depression syndrome

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 103, Issue 4, 2003, Pages 42-47

  Krupina, N A ^a   Krizhanovsky, G N ^a  

^a NONE

Author keywords

Disregulation; Dopamine; Experimental depression like syndrome; Model

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL; CHEMICALLY INDUCED DISORDER; CORPUS STRIATUM; DEPRESSION; DISEASE MODEL; METABOLISM; RAT; REVIEW; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; RATS; RATS, WISTAR;

EID: 0043198613     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Besson A., Priral A.M., Eschalier A., Eialip J. Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm. Pharmacol Biochem Behav 1999; 64: 3: 541-548.
2. Biana G. Antidepressant-like properties of some serotonin receptor ligands and calcium channel antagonists measured with the forced swimming test in mice. Pol J Pharmacol 1998; 50: 2: 117-124.
3. Bonhomme N., Esposilo E. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol 1998; 18: 6: 447-454.
4. Bowden C, Cheelham S.C., LowtherS. et al. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res 1997; 769: 1: 135-140.
5. Brown A.S., Gershon S. Dopamine and depression. J Neural Transmission 1993; 91: 1: 75-109.
6. Calabresi P., De Murtas M., Bemardi G. The neostriatum beyond the motor function: experimental and clinical evidence. Neurosci 1997; 78: 1: 39-60.
7. Caligiuri M.P., Ellwanger J. Motor and cognitive aspects of motor retardation in depression. J Affect Disord 2000; 57: 1-3, 83-93.
8. Castilla C.I., Castilla A., Gurpegui M. Opioid peptides and immunodisfunction in patients with major depression and anxiety disorders. J Physiol Biochem 1998; 54: 4: 203-215.
9. Charlton C.G. Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: a model that main explain the occurrence of depression in Parkinson's disease. Life Sci 1997; 61:5: 495-502.
10. Delgado P.L. Depression: the case for a monoamine deficiency. J Clin Psychiat 2000; 61: Suppl 6: 7-11.
11. Devanand D.P., Bowers M., Hoffman F.J., Nelson J.C. Elevated plasma homovanillic acid in depressed females with melancholia and psychosis. Psychiat Res 1985; 15: 1: 1-4.
12. Diehl D.J., Gershon S. The role of dopamine in mood disorders. Compr Psychiat 1992; 33: 2: 115-120.
13. Drevels W.C., Videen T.O., Price J.L. et al. A functional anatomical study of unipolar depression. J Neurosci 1992; 12: 9: 3628-3641.
14. Fedoroff J.P., Starkstein S., Forrester A.J. et al. Depression in patients with acute traumatic brain injury. Am J Psychiat 1992; 149: 918-923.
15. Fibiger H.C. Neurobiology of depression: Focus on dopamine. In: Depression and Mania. From neurobiology to treatment. New York 1995; 1-17.
16. Fritze J. The Adrenergic-Cholinergic Imbalance Hypothesis of Depression: A Review and a Perspective. Rev Neurosci 1993; 4: 1: 63-93.
17. Fuller R. W. Comparison of MPTP and amphetamines as dopaminergic neurotoxins. In: Neurotoxins and neurodegenerative disease. Annals of the New York Academy of Sciences. New York 1992; 648: Part IV: 87-95.
18. Geoffroy M., Mogilnicka E., Nielsen M., Rafaehen O.J. Effect of nifedipine on the shuttlebo. x escape deficit induced by inescapable shock in the rat. Eur J Pharmac 1988; 154: 3: 277-283.
19. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. In: Neurotoxins and neurodegenerative disease. Annals of the New York Academy of Sciences. New York 1992; 648: Part III: 42-62.
20. Gluck-Vanlaer N., Fallet A., Plas J., Chevalier J.F. Depression and calcinosis of the basal ganslia: apropos of a case. Encephale 1996; 22: 2: 137-1131
21. Hall F.S., Wilkinson L.S., Humby T. et al. Isolation rearing in rats: pre-and postsynaptic changes in striatal dopaminergic system. Pharmacol Biochem Behav 1998; 59: 4: 859-872.
22. Inoe T., Izumi T., Homma H. et al. Survey and treatment strategy of antidepressant-resistant depression. Seishin Shinkeidaku Zasshi 1996; 98: 56: 329-342.
23. KapurS., Mann J.J. Role of the dopaminergic system in depression. Biol Psychiat 1992; 32: 1-17.
24. Kiefer G., Fischer IK, Feuerstein T.J. Effects of amitriptylinoxide, doxepine and clozapine on N-methyl-D-aspartate-evoked release of [3H]-acetylhoIine in rat caudatoputamen. Arzneimittelforschung 1999; 49: 10: 820-823.
25. Kostrzeva R.M., Brus R., Perry K.W. Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system. Pol J Pharmacol 1999; 51: 39-47.
26. Laasonen-Balk T., Kuikka J., Viinamaki H. et al. Striatal dopamine transporter density in major depression. Psychopharmacoloay (Berl) 1999; 144: 3: 282-285.
27. Lambert G., Johansson M., Agren H., Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiat 2000; 57: 8: 787-793.
28. Lammers C.H., Diaz J., Schwartz J.C., Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatment. Mol Psychiat 2000; 5: 4: 378-388.
29. Leonard B.E. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997; 7: 2: Suppl I: S11-S16.
30. Lopez-Villegas D., Kulisevsky J., Deus J. et al. Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification. Arch Neurol 1996; 56: 3: 251-256.
31. McCracken J.T., Poland R.E., Lulchmansingh P., Edwards C. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine. Biol Psychiat 1997; 42: 577-584.
32. Miller H.L., Delgado P.L., Salomon R.M. et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiat 1996; 53: 2: 117-128.
33. Miller H.L., Delgado P.L., Salomon R.M. et al. Effects of a-methyl-paratyrosine (AMPT) in drug-free depressed patients. Neuropsy-chopharmacology 1996; 14: 3: 151-157.
34. Mouret J., Lemoine P., Minult M.P. Marqueurs polygraphiques, cliniques et therapeutiques des deepressions dopamino-deependantes. C.R. Acad Sci (Paris) 1987; 305: Seer III: 301-306.
35. Mouret J., Lemoine P., Minult M.P., Robelin N. L-tyrosine cures, immediate and long term, dopamine-dependent depressions. C.R. Acad Sci (Paris) 1988; 306: 3: 396-398.
36. Nathan K.I., Musselman D.L., SchatzbergA.F., NemeroffCh. B. In: A.F. Schatzberg, Ch.B. Nemeroff (eds.). Biology of mood disorders. Textbook of psychopharmacology. Washington, London 1995; 439-477.
37. Nierenberg A.A., Dougherty D., Rosenbaum J.F. Dopaminergic agent and stimulation as antidepressant augmentation strategies. J Clin Psychiat 1998; 59: 60-63.
38. Poncel M., Habib M. Isolated involvement of motivated behavior and basal ganglia diseases. Rev Neurol 1994; 150: 8-9: 588-593.
39. Puzinski S., Rode A., Zaluska M. Studies on biogenic amine metabolizing enzymes (DBH, COMT, MAO) and pathogenesis of affective illness. Acta Psychiat Scand 1983; 67: 89-95.
40. Roy A., Pickar D., Linnoila M. et al. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiat Res 1985; 15: 281-292.
41. Sato R., Bryan R.N., Fried L.P. Neuroanatomic and functional correlates of depressed mood: the cardiovascular health study. Am J Epidemiol 1999; 150: 9: 919-929.
42. Schildkraut J.J., Kopin I.J., Schanberg S.M., Durell J. Norepinephrine metabolism and psychoactive drugs in the endogenous depressions. 1968 [classical article]. Pharmacopsychiatry 1995; 28: Suppl I: 24-37.
43. Simon B., Appel J.B. Dopaminergic and serotonergic properties of fluoxetine. Prog Neuropsychopharmacol Biol Psychiat 1997; 21: 1: 169-181.
44. Simpson S., Baldwin R.S., Jackson A., Burns A.S. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 1998; 28: 5: 1015-1026.
45. Small J. G. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990; 26: 1: 25-36.
46. Soares J.C., Mann J.J. The anatomy of mood disorders-review of structural neuroimaging studies. Biol Psychiat 1997; 41:1: 86-106.
47. Slahl S.M. Mixed depression and anxiety: serotonin^ receptors as a common pharmacologic link. J Clin Psychiat 1997; 58: Suppl 8: 20-26.
48. Slarkstein S.E., Robinson R.G., Price T.R. Comparison of cortical and subcortical lesions in the production of post-stroke mood disorders. Brain 1987; 110: 1045-1059.
49. Steffens D.C., Helms M.J., Krishnan K.R., Burke G.L. Cerebrovascular disease and depression symptoms in the cerebrovascular health study. Stroke 1999; 30: 10: 2159-2166.
50. Takada M., Li Z.K., Hattori T. Intracerebral MPTP injections in the rat cause cell loss in the substantia nigra, ventral tegmental area and dorsal raphe. Neurocsi Lett 1987; 78: 2: 145-150.
51. Turski L., Klockgether T.H., Turski W. et al. Substantia nigra and motor control in the rat: effect of intranigral a-kainate and y-D-glutamylaminomethyl sulphonate on motility. Brain Res 1987; 424: 37-48.
52. Verbanck P., Chockaert P. Rational use of antidepressant in general medicine. Rev Med Bux 1996; 17: 224-229.
53. Willner P. Sensitization of dopamine D2- or D3-type receptors as a final common pathway in antidepressant drug action. Clin Neurop-harmacol 1995; 18: Suppl 1: S49-S56.
54. Zarifian E. La dopa et les agonistes dopaminergiques dans la deepression. Encephale 1979; 5: 665-670.